TG Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $14.27
- Today's High:
- $15.06
- Open Price:
- $15
- 52W Low:
- $3.48
- 52W High:
- $19.59
- Prev. Close:
- $14.85
- Volume:
- 2448346
Company Statistics
- Market Cap.:
- $2.20 billion
- Book Value:
- 0.426
- Revenue TTM:
- $2.79 million
- Operating Margin TTM:
- -6924.2%
- Gross Profit TTM:
- $2.52 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -42.05%
- Return on Equity TTM:
- -134.13%
Company Profile
TG Therapeutics Inc had its IPO on 1995-12-14 under the ticker symbol TGTX.
The company operates in the Healthcare sector and Biotechnology industry. TG Therapeutics Inc has a staff strength of 226 employees.
Stock update
Shares of TG Therapeutics Inc opened at $15 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $14.27 - $15.06, and closed at $14.63.
This is a -1.48% slip from the previous day's closing price.
A total volume of 2,448,346 shares were traded at the close of the day’s session.
In the last one week, shares of TG Therapeutics Inc have increased by +2.67%.
TG Therapeutics Inc's Key Ratios
TG Therapeutics Inc has a market cap of $2.20 billion, indicating a price to book ratio of 10.8774 and a price to sales ratio of 249.2734.
In the last 12-months TG Therapeutics Inc’s revenue was $2.79 million with a gross profit of $2.52 million and an EBITDA of $-192536000. The EBITDA ratio measures TG Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, TG Therapeutics Inc’s operating margin was -6924.2% while its return on assets stood at -42.05% with a return of equity of -134.13%.
In Q4, TG Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 96.6%.
TG Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TG Therapeutics Inc’s profitability.
TG Therapeutics Inc stock is trading at a EV to sales ratio of 198.8193 and a EV to EBITDA ratio of -4.3494. Its price to sales ratio in the trailing 12-months stood at 249.2734.
TG Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $193.57 million
- Total Liabilities
- $53.20 million
- Operating Cash Flow
- $16.27 million
- Capital Expenditure
- $3000
- Dividend Payout Ratio
- 0%
TG Therapeutics Inc ended 2023 with $193.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $193.57 million while shareholder equity stood at $58.59 million.
TG Therapeutics Inc ended 2023 with $305000.00 in deferred long-term liabilities, $53.20 million in other current liabilities, 146000.00 in common stock, $-1527033000.00 in retained earnings and $799000.00 in goodwill. Its cash balance stood at $102.30 million and cash and short-term investments were $161.68 million. The company’s total short-term debt was $1,581,000 while long-term debt stood at $71.14 million.
TG Therapeutics Inc’s total current assets stands at $168.27 million while long-term investments were $12.40 million and short-term investments were $59.37 million. Its net receivables were $0 compared to accounts payable of $42.02 million and inventory worth $0.
In 2023, TG Therapeutics Inc's operating cash flow was $16.27 million while its capital expenditure stood at $3000.
Comparatively, TG Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $14.63
- 52-Week High
- $19.59
- 52-Week Low
- $3.48
- Analyst Target Price
- $19.88
TG Therapeutics Inc stock is currently trading at $14.63 per share. It touched a 52-week high of $19.59 and a 52-week low of $19.59. Analysts tracking the stock have a 12-month average target price of $19.88.
Its 50-day moving average was $15.9 and 200-day moving average was $9.27 The short ratio stood at 6.88 indicating a short percent outstanding of 0%.
Around 885.7% of the company’s stock are held by insiders while 6459.6% are held by institutions.
Frequently Asked Questions About TG Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.